Introduction
In an era where the intersection of science, equity, and sustainability is more critical than ever, Alnylam is a leading biotechnology company committed to delivering transformative health solutions while driving meaningful societal and environmental impact. Rooted in its pioneering RNAi platform, the company embraces a holistic approach to corporate responsibility - one that prioritizes not just scientific innovation, but also access to care, climate action, and inclusive growth.
Alnylam’s sustainability initiative reflects its commitment to advancing RNAi therapeutics while fostering a healthier, more equitable, and sustainable world. Centered around six core pillars - Patients, Science, Employees, Communities, Planet, and Governance - the company emphasizes patient access, innovation in rare and prevalent diseases, workplace inclusivity, and global community engagement. Key achievements include third-party verified emissions data, green power purchase agreements for their two manufacturing sites, and expanded access to therapies in over 70 countries. Alnylam’s integrated approach to corporate responsibility aligns with global sustainability standards and showcases its dedication to long-term social and environmental impact.
Alnylam: Scale and Scope
Global Presence
21+
Locations
Emission Sources
100+
Across Operations
Emission Factors
174+
Including Custom EFs
Avg. Data Points
25,000+
Per Month
